Maladies auto-immunes, Immunologie
|
Thérapie cellulaire
August 28, 2026
Carl June, MD, and member of CellCarta's Scientific Advisory Board, join Christopher Ung, our Chief Scientific Business Officer, for a conversation on advancements in immunotherapies, why ex vivo CAR-Ts aren't going to disappear, and what's next for the field.
